Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout that ...

The Department of Health and Human Services has announced a plan to end mRNA vaccine work funded by the Biomedical Advanced ...

Orchestra BioMed reported that it has secured over $111 million in financing through a series of transactions and ...

Alcon is building out its portfolio of lens implants, with a $1.5 billion deal to acquire the flagging Staar Surgical and its ...

Terns Pharmaceuticals is planning to stop investing in metabolic disease clinical development at the end of 2025, starting a countdown to potential deals for assets including a midphase oral obesity ...

Pfizer's beleaguered obesity strategy has hit another setback as the pharma jettisoned its third and final GLP-1 agonist, ...

Imunon has confirmed the deprioritization of its COVID-19 vaccine program. With the company’s cash reserves falling below $5 ...

BioMarin Pharmaceutical is continuing to slim down its pipeline, this time ending work on a preclinical phenylketonuria (PKU) ...

As part of a "strategic alignment" of its pipeline, BioNTech is laying off 90 workers in R&D and corporate roles across two sites in Maryland and Massachusetts, a spokesperson told Fierce. | As part ...

A phase 2b trial of HMNC Brain Health’s depression drug candidate has missed its primary endpoint. But while the ex-Sanofi molecule failed to move the needle in the overrall population, results in ...

OrbiMed’s website lists 134 biopharma companies across the firm’s portfolio. Recent investments the firm has participated in ...

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). | Vertex ...